A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — IMAGINATION

Primary IgA Nephropathy Clinical Trial

Official title:
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05797610
Study type	Interventional
Source	Hoffmann-La Roche
Contact	WA43966 https://forpatients.roche.com/
Phone	888-662-6728 (U.S. Only)
Email	global-roche-genentech-trials@gene.com
Status	Recruiting
Phase	Phase 3
Start date	August 8, 2023
Completion date	September 30, 2030

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03643965` - Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy	Phase 3
Recruiting	`NCT04557462` - A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy	Phase 3
Active, not recruiting	`NCT04541043` - Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)	Phase 3
Recruiting	`NCT05847920` - Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy	Phase 2
Recruiting	`NCT02765594` - Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy	Phase 4
Not yet recruiting	`NCT02712697` - Integrative Medicine of IgA Nephropathy	N/A
Completed	`NCT04887532` - A Trial of HR19042 Capsule in Healthy Chinese Subjects	Phase 1
Not yet recruiting	`NCT06137768` - A Trial of HRS-5965 Tablets in Primary IgA Nephropathy	Phase 2
Completed	`NCT02351752` - Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study	Phase 4
Completed	`NCT04014335` - A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy	Phase 2
Completed	`NCT01738035` - The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease	Phase 2